Ranjit Bindra

Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT.

Modifi Biosciences is a company based in New Haven, CT that specializes in direct DNA modification to develop novel therapeutics that target tumor-associated DNA repair defects. Modifi Bio has offices and laboratories at the Elm City Bioscience Center, a newly renovated 110,000 square-foot facility within walking distance of Yale that supports emerging New Haven biotechnology companies. The company's goal is to improve the standard of cancer therapy and patient care. The team includes world-renowned scientists, clinicians, and experienced biotech entrepreneurs with expertise in synthetic chemistry, DNA repair, and translational research in oncology. The company was founded by Ranjit S. Bindra and Seth Herzon.

Athena Therapeutics LLC has developed innovative methods to identify and study altered states of NAD metabolism and is creating new types of small molecules to target multiple nodes in NAD synthesis pathways. Athena Therapeutics is based in New Haven, CT and was founded by Ranjit S. Bindra and Charles Brenner. The company has recruited a team of researchers with expertise in NAD metabolism, led by Dr. Emmanuel Burgos, and has established a scientific advisory board of world experts, including Professor Vern Schramm and Dr. Leonard Post.

National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD.

Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to: correct mutations, leading to restoration of normal function of key gene products, alter levels of gene expression, potentially turning genes on or off, functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells. Through the use of SBIR grants and seed funding, it will advance preclinical projects targeting the human globin gene for applications on sickle cell anemia and beta-thalassemia, the CCR5 receptor for the HIV/AIDS population, and genetic mutations responsible for the liposomal storage disease, Gaucher's. Genetic alteration of stem cells has the potential to dramatically impact the efficacy of stem cell therapy for human disease. Due to the accessibility of HSC without bone marrow transplants, the company is currently focused on blood based genetic diseases. As advances in human stem cell biology are realized, however, it is possible to envision applications in a broad array of human genetic diseases. Moreover, because the DNA modifications introduced to stem cells are stable and heritable; this technology offers the hope of curing certain genetic diseases. Its approach does not rely on viral vectors and corrects the patients own cells, eliminating potential immune reactions. This approach is classified as Cellular Therapy, which provides another level of safety to the patient.